DarshanTalks Podcast

Send us Fan Mail In this podcast, five crucial considerations for obtaining approval for a digital speaker program are discussed: 1. Privacy Compliance:    - Consider where audience data will be stored and ensure compliance with privacy laws (TCPA, CCPA, GDPR, etc.).    - Prioritize secure handling of sensitive information and always obtain audience consent. 2. Transparency and Disclosure:    - Ad...

Send us Fan Mail he recently issued FDA guidance mandates manufacturers, packers, and distributors to adhere to new standards, emphasizing mandatory product and facility registrations, creation of safety substantiation information, and implementation of adverse event reporting. Daron breaks down key definitions, clarifies information submission processes, and discusses public accessibility.  Tune...

Send us Fan Mail In this podcast episode, we'll uncover five strategies to expedite the digital promotion review process. Starting with 1. Policy creation and training emphasizes aligning policies across platforms, incorporating key stakeholders' expectations, and ensuring consistency with relevant agreements and guidelines.  2. Pre-review meetings with marketing teams help establish a s...

Send us Fan Mail Darshan Kulkarni delves into the recently released draft guidance by the Center for Devices and Radiological Health (CDRH) outlining best practices for selecting a predicate device when preparing a 510(k) submission. This guidance underscores four key considerations. The draft guidance emphasizes the significance of technological characteristics. If the new device shares the same...

Send us Fan Mail Darshan Kulkarni discusses the FDA's IT strategy for 2024 to 2027. The FDA aims to create a unified FDA ecosystem, promote cross-functional collaboration, and foster a more integrated organizational culture. Key goals include  strengthening IT infrastructure,  modernizing enterprise services, and  optimizing the IT services portfolio for stable, resilient, and adaptive soluti...

Send us Fan Mail In a significant update on September 19th, Samuel Levine, Director of the #FTC's Bureau of Consumer Protection, outlined the agency's key priorities at the National Advertising Division's annual conference. Levine emphasized a three-pillar enforcement agenda.  The first pillar targets practices causing substantial consumer harm,  While the second aims not only to ce...

Send us Fan Mail This week, a data breach was disclosed by 23andMe, affecting 6.9 million users and compromising their genetic data information. The incident raises significant concerns about data privacy and security. It's important to note that while some perceive this as a violation of HIPAA, it typically doesn't apply to direct-to-consumer genetic testing services like 23andMe, as th...

Send us Fan Mail Guest Istvan Fekete discusses what large academic medical institutions are responsible for that sponsors and other commercial entities are generally not. Key considerations include the complexities of handling publication rights, the impact of tax-exempt municipal bonds on project restrictions, ensuring equal patient treatment, the reality of universities generating revenue from i...

Send us Fan Mail In this video,, the focus is on the growing interest in digital engagement programs among FDA-regulated companies, but it also addresses the concerns raised by regulatory agencies such as the FDA, DOJ, FTC, and OIG. The discussion revolves around the risk-based review of outward-facing information shared by medical device companies. The podcast delves into seven hierarchical layer...

Send us Fan Mail Darshan Kulkarni talks about how the generic drug industry is facing several challenges that are impacting profitability, including: 1. Pressure from insurers to lower prices, 2. Rising costs of manufacturing and distribution, 3. Inflation, 4. Supply chain disruptions and 5. Increased competition from other generic companies Pharmacies are fighting back against these challenges by...

Send us Fan Mail Recently, Celia Sandhya Daniels was announced to be one of the top 20 LGBTQ leaders in Bio Pharma by Endpoints News. In this episode, We're venturing into the captivating world of Diversity, Equity, and Inclusion (DEI) in the realm of pharmaceuticals and healthcare. Get ready for a journey that will unravel the mysteries and intricacies of DEI! We’re joined by Celia Sunday Da...

Send us Fan Mail The case study on academic research center misconduct highlights the urgency to address and prevent such issues in the field. Instances of research misconduct, as exemplified by the Miami case, have drawn the attention of regulatory agencies like the Department of Justice, emphasizing the need for stringent oversight and ethical conduct. Examining the fictional case of Padre Pio H...

Send us Fan Mail Planning to incorporate artificial intelligence into your business in 2024? Stay informed about the Federal Trade Commission's (FTC) expectations. In his discussion, Darshan Kulkarni highlights the FTC's recommendations for AI: FTC expects that AI will foster fair, open and competitive markets, FTC intends to use its tools to challenge unfair and deceptive practices invo...

Send us Fan Mail Jessica Thompson discusses how project management can be a game-changer in clinical research.  We talk about how poor project management can lead to delays, cost overruns, and regulatory violations, and that lawyers can play a role in ensuring that clinical research projects are managed effectively. Thompson emphasized the need for early planning and communication between all stak...

Send us Fan Mail Virginia Tech recently received a $50 million gift from the Red Gates Foundation for Health Sciences research expansion. In light of recent news about research fraud prosecuted by the Department of Justice, it is crucial for the Fralin Biomedical Research Institute to implement robust research integrity policies. Here are five key steps that the institute can take to address resea...

Send us Fan Mail We discuss the 7 things to do before closing your pharmacy: 1. Return your DEA registration, 2. Notify the Board of Pharmacy, 3. Dispose of controlled substances appropriately, 4. Inventory your pharmacy and create a clear inventory list, 5. Keep all documentation, especially for controlled substances, for at least 2 years, 6. Know where your records are stored, as the DEA may req...

Send us Fan Mail The FDA's recent decision to cease its enforcement discretion for lab-developed tests (LDTs) has significant implications for developers. To ensure compliance, developers must adhere to a rigorous process.   Key steps include: 1) Develop a risk-based framework- 0:39 - 1:03 2) Get pre-market clearance or approval- 1:04 - 1:37 3) Quality control and quality assurance- 1:38 - 2:...

Send us Fan Mail On September 5th, 2023, a Miami jury found a medical clinic owner and pharmacist guilty of falsifying and fabricating clinical trial data.   We highlight the significance of pharmacists recognizing red flags indicating potential fraud, including patients unknowingly or involuntarily enrolled in clinical trials.   Beyond the broader impact on public trust, pharmacists could face sp...

Send us Fan Mail In this episode, guest Dave Bulger delves into the intricate role of AI, questioning whether it functions as a creator, a copycat, or perhaps both. Dave Bulger, delves into the world of #AI , highlighting the distinction between AI and large language models (LLMs). He exposes the limitations of generative AI, raises concerns about copyright in content generation, and explores AI&a...

Send us Fan Mail The FDA has taken action by sending warning letters to eight companies that have been marketing unapproved eye products, potentially violating federal laws and risking consumer health.  These companies include Boiron Inc, CVS Health, Dr. Vitamin Solutions, Natural Ophthalmics Inc., OcluMed LLC, Similasan USA or Similasan AG, TRP Company Inc., and Walgreens Boots Alliance Inc.  The...

Send us Fan Mail FDA is suggesting the use of one-pagers to provide essential drug information to patients. Past attempts faced challenges, such as one-size-fits-all content and patient trust issues.    Darshan emphasizes that while the FDA's proposal is a step in the right direction, it must ensure that these one-pagers are comprehensive, accurate, and transparent. Patients often rely on hea...

Send us Fan Mail  In this episode, we’ll discuss how to speed up your marketing approval process with these must know concept review tips. We will talk to Heather McFalls, Director of AD Promo at Organon. In this interview we will address the following questions:  1.    How often do people do concept reviews?  2.    Is it useful to have an attorney at the concept review stage?  3.    Is the role o...

Send us Fan Mail  We explore the world of biohacking, with a particular focus on the emerging trend of "testosterone parties." These biohacking practices raise concerns regarding safety, efficacy, and misleading promotion, as many unapproved applications lack scientific support. It's worth noting that the FBI oversees biohacking, despite its primary purpose not being generalized res...

Send us Fan Mail  AI expert Dave Bulger, delves into the world of #AI, highlighting the distinction between AI and large language models (LLMs). He exposes the limitations of generative AI, raises concerns about copyright in content generation, and explores AI's potential impact across industries. Dave underscores that while LLMs can generate text, they lack true understanding. The conversati...

Send us Fan Mail  We explore the world of biohacking, with a particular focus on the emerging trend of "testosterone parties." These biohacking practices raise concerns regarding safety, efficacy, and misleading promotion, as many unapproved applications lack scientific support. It's worth noting that the FBI oversees biohacking, despite its primary purpose not being generalized res...